Abbott | Neuromodulation

A huge thank you to everyone who connected with us at #ASPN2026! Across the ASPN 5K, Accelerator Reception, scientific symposia, and ASPN’s Faculty Reception — the conference was filled with meaningful conversations, shared learning, and collaboration focused on advancing chronic pain care. We appreciate the opportunity to share new clinical evidence and innovations shaping the future of neuromodulation. #Neuromodulation #ChronicPainManagement MAT-2677157 v1.0 | Item approved for use in the US.

Last week, our Lunch Symposium at #ASPN2026 offered a clear view into where chronic pain care is headed. Led by Iden M. Cowan MD, Tim Deer, MD, David M. Dickerson, MD, FASA, Steven Falowski, and Pankaj Mehta MD, the session covered clinical evidence supporting BurstDR™ stimulation and FlexBurst360™ therapy, expert perspectives on DRG therapy and MRI labeling updates, and access to care. It’s great to see this community come together with a shared commitment to advancing care for patients living with chronic pain. Important Safety Info: bit.ly/4gL7p46 #Neuromodulation #ChronicPainManagement #BurstDR MAT-2677155 v2.0 | Item approved for use in the US.

As we wrapped up our Accelerator Reception at #ASPN2026, we connected with many talented early-career physicians ready to advance their practice. Here’s what Anuj Shah D.O, Abbott Accelerator and co-chair of American Society of Pain and Neuroscience ASPN's Young Innovators, took away: “Being able to have access to excellent mentors from around the country who are doing advanced neuromodulation... In addition to this, behind the procedures, we're able to get access to the data supporting all this evidence. It’s something we can share with our patients.” That’s what the Accelerator Program was designed to do. Provide education that directly translates to patient care. Proud to be supporting the next generation of physicians. Hear the full interview below. Support provided by Abbott. The physician(s) worked on Abbott’s behalf. The information is consistent with applicable FDA guidelines. This video is not intended for reposting or redistribution on non-Abbott websites or other external channels without explicit, written consent. Important Safety Info: https://bit.ly/4gL7p46 MAT-2677723 v1.0 | Item approved for use in US

As #ASPN2026 continues, there’s still time to stop by our booth and get hands-on with Proclaim™ DRG therapy and our latest neuromodulation technology. See firsthand how our platforms are advancing the way chronic pain is managed. Our Abbott team is here to connect with you and answer your questions. We hope to see you over at our booth just inside the doors or at one of our upcoming events: Find out where we will be next here: https://abbo.tt/4wi2Brs Important Safety Info: https://bit.ly/4gL7p46 #AbbottProud #Neuromodulation #ChronicPainManagement MAT-2677154 v1.0 | Item approved for use in the US.

Clinical evidence and real-world experience took center stage at our #ASPN2026 Topics in Neuromodulation Symposium (TINS). Drs. Dirk De Ridder, Steven Falowski, Denis Patterson, Dawood Sayed, and Jackie Weisbein reviewed highlights of their experience with BurstDR™ stimulation and discussed how FlexBurst360™ therapy is helping deliver meaningful, lasting outcomes for people living with chronic pain.¹ We appreciate the perspectives shared and thank you to everyone who joined the conversation. Learn more about ASPN: https://abbo.tt/4wi2Brs Important Safety Info: bit.ly/4gL7p46 #Neuromodulation #PainManagement References: 1. Deer T, Slavin KV, Amirdelfan K, et al. Success using neuromodulation with BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. Neuromodulation. 2018;21(1):56-66. doi:10.1111/ner.12698 MAT-2677156 v1.0 | Item approved for use in the US.

There’s more to explore at #ASPN2026! Visit our booth to learn how we're advancing chronic pain care through innovations designed to expand patient access and support clinical decision making. Whether you're interested in the latest evidence, technology, or educational resources, our team is here to answer your questions and continue the conversation. Check out the agenda: https://abbo.tt/4wi2Brs Important Safety Info: https://bit.ly/4gL7p46 #Neuromodulation #ChronicPainManagement MAT-2677154 v1.0 | Item approved for use in the US.

Innovation that matters. Outcomes that endure.¹ At #ASPN2026, our clinical program will highlight how we’re advancing the way chronic pain is assessed, studied, and managed in real-world practice. Across our moderated sessions, we’ll share new insights focused on scalable data capture, validated outcomes, and long-term clinical benefits. Check out our podium presentations and posters: https://abbo.tt/4wi2Brs #Neuromodulation #ChronicPainManagement 1. Abbott. BurstDR™ Stimulation SCS Clinical Consistency Memo. 2026.

Innovation meets evidence at #ASPN2026. Our lunch symposium will showcase a comprehensive approach to chronic pain management, highlighting the clinical evidence behind BurstDR™ stimulation and FlexBurst360™ therapy, as well as recent advancements in DRG therapy, MRI labeling updates, and innovations designed to expand patient access to care. Join Iden M. Cowan MD, Tim Deer, MD, David M. Dickerson, MD, FASA, Steven Falowski, and Pankaj Mehta MD as they share insights on meaningful pain relief and better outcomes for patients with chronic pain. Important Safety Info: https://bit.ly/4gL7p46 #Neuromodulation #ChronicPainManagement #BurstDR

The future of neuromodulation is here! At our #ASPN2026 Topics in Neuromodulation Symposium (TINS) Dinner, we'll spotlight a decade of impact with BurstDR™ stimulation and explore how the next generation of this technology, FlexBurst360™ therapy, can help treat more pain areas.¹,² Looking forward to hearing experts share real-world insights, clinical experience, and perspectives on the next chapter of innovation in neuromodulation. Register now: https://abbo.tt/4wi2Brs Dirk De Ridder | Steven Falowski | Denis Patterson | Dawood Sayed | Jackie Weisbein Important Safety Info: https://bit.ly/4gL7p46 #Neuromodulation #PainManagement 1. Abbott. NeuroSphere Clinician Programmer, Eterna SCS System. 2025. 2. Abbott. NeuroSphere Clinician Programmer Spinal Cord Stimulation Systems Model 3874. 2025.

Now published: 24-month data from the DISTINCT nonsurgical back pain study. Results showed sustained improvements with BurstDR™ stimulation in pain (NRS), function (ODI) and psychological status (PCS) in patients with refractory nonsurgical chronic low back pain (NS-CLBP). The DISTINCT study was a prospective, multicenter randomized controlled trial evaluating the effectiveness of BurstDR™ stimulation in the treatment of NS-CLBP compared with conventional medical management. In the published 24-month analysis, 77% of spinal cord stimulation (SCS) patients reported a ≥50% reduction in pain. Clinically significant, sustained improvements were also reported in functionality and psychological status in 72.4% and 79.1% of SCS patients, respectively.¹ Read the data in the North American Spine Society Journal: https://bit.ly/4eZ1PZG Important Safety Info: https://bit.ly/4uYVxQA #SpinalCordStimulation #ChronicPain #Neuromodulation 1. Yue, James J., et al. "Passive Recharge Burst Spinal Cord Stimulation for the Treatment of Refractory Nonsurgical Low Back Pain: 24-month Results from a Prospective Randomized Controlled Trial and Predictors of Success." North American Spine Society Journal (NASSJ) (2026): 100911.